WO2026120497 - STABLE RADIONUCLIDE COMPLEX SOLUTIONS
National phase entry is expected:
Publication Number
WO/2026/120497
Publication Date
11.06.2026
International Application No.
PCT/IB2025/062362
International Filing Date
03.12.2025
Title **
[English]
STABLE RADIONUCLIDE COMPLEX SOLUTIONS
[French]
SOLUTIONS STABLES DE COMPLEXES DE RADIONUCLÉIDES
Applicants **
NOVARTIS AG
Inventors
BICOCCHI, Giacomo
DELL'ISOLA, Antonio
FERRERO, Valentina Elisabetta Viviana
TEDESCO, Mattia
Priority Data
24217898.6
05.12.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3437 | |
| EPO | Filing, Examination, Granting | 28833 | |
| Japan | Filing, Examination, Granting | 3289 | |
| South Korea | Filing, Examination, Granting | 4274 | |
| USA | Filing, Examination, Granting | 11540 |
Total:
51,373
Contact Us
Abstract[English]
The present invention relates to aqueous pharmaceutical solutions comprising an alpha-particle emitting radionuclide that provide for radiochemical purity over an extended period, resulting in a product is that is suitable for use as commercial drug product for therapeutic purposes.[French]
La présente invention concerne des solutions pharmaceutiques aqueuses comprenant un radionucléide émetteur de particules alpha, assurant une pureté radiochimique sur une période prolongée, aboutissant à un produit adapté à une utilisation en tant que médicament commercial à des fins thérapeutiques.